BIOVIE INC
BIVINASDAQTrading Snapshot
- Day Range
- $1.52 – $1.57
- 52-Week Range
- $0.82 – $3.79
- Volume
- $3.78B
- Avg Volume
- $4.81B
- Shares Outstanding
- 7.5M
- Next Earnings
- Nov 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $829,400
- Last Q Revenue
- $194,613
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.15
- Dividend Yield
- —
- Dilution (1yr)
- −4.8%
Why Investors Own BIVI
- ✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIOVIE INC
BIVI
StockOtter · stockotter.spaceAbout BIOVIE INC
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
BioVie Highlights Bezisterim Phase II Data, Eyes FDA Path for Phase III Trials
BioVie (NASDAQ: BIVI) outlined Phase II results for its investigational drug bezisterim in Long COVID and Parkinson's disease, while detailing plans to seek FDA feedback on potential Phase III programs. President and CEO
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
What's Going On With BioVie Stock on Tuesday?
Clinical-stage biopharmaceutical firm BioVie Inc. (NASDAQ:BIVI) stock is trading lower after the company shared topline results from its Phase 2 ADDRESS-LC study evaluating bezisterim in Long COVID patients.
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)